Mining the genome for combination therapies

被引：16

作者：

Golub, TR

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Whitehead Inst, MIT, Ctr Genome Res, Cambridge, MA 02142 USA

[3] Howard Hughes Med Inst, Chevy Chase, MD USA

来源：

NATURE MEDICINE | 2003年 / 9卷 / 05期

关键词：

D O I：

10.1038/nm0503-510

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The evaluation of drug combinations for cancer treatment has progressed slowly through methodical clinical research. A new study examining gene expression profiles could signal a shift in the approach to combination therapy.

引用

页码：510 / 511

页数：2

共 4 条

[1] Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells [J].

Cheok, MH ;

Yang, WL ;

Pui, CH ;

Downing, JR ;

Cheng, C ;

Naeve, CW ;

Relling, MV ;

Evans, WE .

NATURE GENETICS, 2003, 34 (01) :85-90

[2] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[3] Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL consortium protocol 87-01 [J].

LeClerc, JM ;

Billett, AL ;

Gelber, RD ;

Dalton, V ;

Tarbell, N ;

Lipton, JM ;

Barr, R ;

Clavell, LA ;

Asselin, B ;

Hurwitz, C ;

Schorin, M ;

Lipshultz, SE ;

Declerck, L ;

Silverman, LB ;

Cohen, HJ ;

Sallan, SE .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :237-246

[4] Acute lymphoblastic leukemia [J].

Pui, CH ;

Evans, WE .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :605-615

← 1 →